Human medicines European public assessment report (EPAR): Ponvory, ponesimod, Multiple Sclerosis, Relapsing-Remitting, Date of authorisation: 19/05/2021, Revision: 3, Status: Authorised
In multiple sclerosis, the immune system (the body’s natural defences) incorrectly attacks the protective sheath around the nerves and the nerves themselves in the brain and spinal cord.
The active substance in Ponvory, ponesimod, blocks T cells and B cells (two types of white blood cells involved in the immune system) inside the lymph nodes. Ponesimod does this by binding to a target (receptor), called the sphingosine-1-phosphate receptor, on the surface of T cells and B cells, which the cells need to leave the lymph nodes. By blocking these cells in the lymph nodes, Ponvory prevents them from traveling towards the brain and spinal cord, thus limiting the damage they cause in patients with multiple sclerosis.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
